The UK NSC is currently consulting on adult screening for dementia and newborn screening for metachromaticsevere leukodystrophycombined (MLD).immunodeficiency (SCID)
To respond to the consultation, click the ‘Submit comments’ green button on the dementia recommendation page (link above), which provides a template for your response. Or you can send an email with your comments to uknsc@dhsc.gov.uk.
This consultation closes at 11.59pm on 9 September 2025.
The UK NSC is currently consulting on newborn screening for severe combined immunodeficiency (SCID)
To respond to the consultation, click the ‘Submit comments’ green button on the SCID recommendation page (link above), which provides a template for your response. Or you can send an email with your comments to uknsc@dhsc.gov.uk.
This consultation closes at 11.59pm on 27 October 2025.
The UK National Screening Committee (UK NSC) runs the following types of public consultations.
Condition recommendation consultations
These relate to whether to screen for a certain condition. They are the most common type of consultation. The UK NSC reviews conditions every 3 years to determine whether it can recommend a screening programme. You can find these conditions in the UK NSC’s recommendations list.
For conditions where there is already a population screening programme, the UK NSC carries out programme change reviews. They relate to how to screen, rather than whether to screen. They are to make recommendations on changing an existing programme, for instance to introduce a new type of screening test.
Information removed on MLD consultation which closed at 11.59pm on 5 August 2025.
17 July 2025
Consultation on screening for dementia added.
7 May 2025
Opening of consultation into screening for Metachromatic leukodystrophy.
4 December 2024
Opening of consultation into a recommendation to offer HPV self-sampling option to under-screened people in the cervical screening programme.
3 October 2024
Consultation open into dental disease screening in children aged 6 to 9 years.
6 March 2024
Closing of consultation into Edwards' syndrome screening pathway modification.
1 March 2024
Addition of consultation into addition of quad test to Edwards' syndrome screening pathway.
20 September 2023
Digital pathology consultation has ended.
7 August 2023
Consultation opens on allowing use of digital pathology in cancer screening programmes.
4 June 2023
Vasa praevia consultation has ended
3 March 2023
Opening of consultation into screening for vasa praevia.
31 October 2022
End of pre-eclampsia consultation
7 October 2022
End of HTLV consultation
9 August 2022
End of iron deficiency anaemia consultation
8 August 2022
opening of consultation on pre-eclampsia
6 July 2022
Consultation opened for human T-lymphotropic virus (HTLV) type 1
5 July 2022
End of autism consultation
9 June 2022
Consultation on lung cancer screening has closed.
11 May 2022
Consultation closed on screening for primary hypertension in children and young people
5 May 2022
Opening consultation on screening for iron deficiency anaemia in children.
11 April 2022
Consultation opened on screening for autism.
14 March 2022
End of consultation on tyrosinaemia.
11 March 2022
Added details that the population screening programme consultation for lung cancer is now open.
21 February 2022
Opening of public consultation on screening for primary hypertension in children and young people.
19 January 2022
Consultation closed for cytomegalovirus.
14 January 2022
End of thyroid disease consultation period
14 December 2021
UK NSC consultation on tyrosinaemia now open.
28 October 2021
Consultation opened into screening for cytomegalovirus (CMV).
18 October 2021
Updated list of current UK NSC consultations to include consultation on thyroid disease.
12 October 2021
Updated the list of current UK NSC consultations.
13 July 2021
Added alcohol misuse and Duchenne muscular dystrophy to the current consultations.
18 May 2021
The UK NSC has started consultations on screening for congenital adrenal hyperplasia, automated grading in diabetic eye screening and the use of AI in breast cancer screening.